Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based Chairman operating in the Health Care space. If you think a Chairman is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Anthony P Mack
Founding Chairman & CEO of Virpax Pharmaceuticals Inc.
Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding Virpax in 2016, Mr. Mack founded Scilex Pharmaceuticals and served as President and CEO until February 2018. Scilex was sold to a publicly-traded company. Mr. Mack founded his first pharmaceutical company ProSolus Pharmaceuticals in 2009, where he served as President before selling the company to Mission Pharmacal in 2015. Mr. Mack has held high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. He has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.
Follow Anthony P Mack:
About Virpax Pharmaceuticals Inc.: Our product candidates are being developed to manage global unmet needs in the areas of cancer and non-cancer pain, PTSD, and CNS Disorder.
_______
Geoffrey Woo
Co-founder & Executive Chairman of Health Via Modern Nutrition
Geoffrey Woo is the Co-Founder & General Partner of Anti Fund.He attended to the Stanford University.
Follow Geoffrey Woo:
About Anti Fund, Archive, Health Via Modern Nutrition: H.V.M.N. leads the way in science, product, and community building around low-carb diets, ketones, and metabolic health.
George Archos
Co-Founder, Chairman and CEO of Verano Holdings
George Archos is the founder & CEO of Verano Holdings. He is a logistics and operations guru. Building on his extensive experience in coordinating complex freight delivery operations, as well as designing and operating highly-successful restaurants, George entered the cannabis industry in 2014 when he founded Ataraxia Grow and Labs in Illinois and was the first to receive authorization to grow medical cannabis out of 21 recipients of the coveted medical licenses. George’s diligence, perseverance, and tireless work ethic have made him one of the cannabis industry’s most successful entrepreneurs. Leveraging his unparalleled devotion to quality and a unique results-oriented approach to the cannabis industry, George has overseen the development of some of cannabis’s most highly-coveted operations and brands. George’s restaurants across the Chicagoland area, including Wildberry Pancakes & Café, Westwood Tavern & Tap and the Scout Waterhouse & Kitchen, all bear the imprint of his relentless devotion to quality and unrivaled customer service, earning him multiple awards and recognition. George’s unique experience, his admirable drive, and his unrelenting commitment to quality, coupled with his capacity to establish, build, and effectively run multi-jurisdictional companies, are an asset to Verano Holdings.
Follow George Archos:
About Verano Holdings: Verano is a vertically integrated, multi-state cannabis operator.
Aaron Kaufman
CEO & Chairman of OpenMed
Follow Aaron Kaufman:
About : OpenMed is a digital innovator in closing care gaps, enabling access to care, and supporting real-time collaboration.
Paul Bisaro
Executive Chairman of Allergan
Paul Bisaro currently serves as Executive Chairman of Allergan and the Company’s Board of Directors. He served as the Chief Executive Officer of Actavis from September 2007 to July 2014. Prior to joining Actavis (then Watson), he was President and Chief Operating Officer of Barr Pharmaceuticals, Inc. (“Barr”) from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel and from 1997 to 1999 served in various additional capacities including Senior Vice President — Strategic Business Development at Barr. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. He also served as a Senior Consultant with Arthur Andersen & Co. Mr. Bisaro received his undergraduate degree in General Studies from the University of Michigan in 1983 and a Juris Doctor from Catholic University of America in Washington, D.C. in 1989.
Follow Paul Bisaro:
About Allergan: Allergan is a global pharmaceutical company.
Brenton Saunders
Chairman, President and Chief Executive Officer of Allergan
Brent Saunders is Chief Executive Officer and President of Allergan plc (formerly Actavis plc). Brenton previously served as Chief Executive Officer and President of Forest Laboratories and had served as a Member of the Board of Directors at Forest since 2011. Brenton has significant healthcare industry expertise and a proven track-record leading business transformations and integrations. Prior to Forest, Brenton was Chief Executive Officer of Bausch + Lomb, a leading global eye health company, serving in this capacity from March 2010 until August 2013. Brenton also held a number of leadership positions at Schering-Plough, including the position of president of Global Consumer Health Care and was named head of integration for the company’s merger with Merck & Co. and for Schering-Plough’s acquisition of Organon BioSciences. Before joining Schering-Plough, Brenton was a Partner and Head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, Brenton was Chief Risk Officer at Coventry Health Care and Senior Vice President, Compliance, Legal and Regulatory at Home Care Corporation of America. Brenton began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. Brenton serves on the Board of Trustees of the University of Pittsburgh. Brenton is also the former Chairman of the New York chapter of the American Heart Association. Brenton is a Member of the Business Council and PhRMA. Brenton earned his MBA from Temple University School of Business, his J.D. from Temple University School of Law and his Bachelor’s degree from the University of Pittsburgh.
Follow Brenton Saunders:
About Allergan, Cisco: Allergan is a global pharmaceutical company.
Brad Cohen
Executive Chairman and Founder of Medcase Health
Brad Cohen is the Executive Chairman and Founder at Medcase Health.
Follow Brad Cohen:
About Brightcom Group (formerly LYCOS Internet Ltd), Edgecase.ai, ESPOT TV, Medcase Health: Medcase’s ever-evolving marketplace of clinicians sits at the intersection between technology and healthcare.
Sam Santhosh
Founder Chairman & Global CEO of MedGenome
Sam Santhosh is the Founder and CEO of MedGenome. He has been an entrepreneur, with over 20 years of experience in the software industry. Currently, he is at the helm of affairs as CEO and promoter of MedGenome Labs Pvt Ltd. Sam sits on the board of a number of companies, both in the US and India. In this role he advises, guides and mentors companies to help them grow and realize their true potential. Prior to this Sam was the CEO and Managing Director of California Software Limited (Calsoft) from 1992 – Feb 2012. He founded Calsoft in 1992 and under Sam’s vision, Calsoft rapidly grew from a niche player in the Silicon Valley to a global player with over 1200 employees and presence in 8 countries. Sam took Calsoft Public and the company is listed the in Indian Stock Exchanges. Sam oversaw the growth of Calsoft in all key areas – Finance, Strategy, Customer Acquisition, and inorganic growth through eight acquisitions including companies in the U.S, UK, Japan, and India. He has been constantly retooling himself and has attended various training programs in different U.S universities including MIT. In 2010, he completed the Executive Education program at the Singularity University in Sunnyvale, California. Sam has an engineering degree and an MBA (majoring in Management Information Systems) from India’s premier institute, IIM Calcutta.
Follow Sam Santhosh:
About Agrigenome, MedGenome: MedGenome develops a genomics-based diagnostics and research solution for healthcare providers to understand the genetic basis of diseases.
Richard Burke
Non-Executive Chairman of the Board of Directors of UnitedHealth Group
Richard Burke is a Non-Executive Chairman of the Board of Directors at UnitedHealth Group.
Follow Richard Burke:
About : UnitedHealth Group is a healthcare company that offers insurance products and services for everyone.
Isaiah Harris
Chairman & Board Member of Cigna
Isaiah Harris is the Chairman of the Board of Directors at Cigna since December 2009 and served as Vice-Chairman of the Board of Directors from July 2009 through December 2009. Isaiah has served as an Independent Trustee of Wells Fargo Advantage Funds (a provider of mutual funds) since 2008 and served as a Member of the Board of Directors at Deluxe Corporation (a provider of customized products and services including financial services and direct checks) from 2004 until 2011. Before his direct role overseeing advertising and publishing, Isaiah served as President of BellSouth Enterprises for BellSouth Corp. in Atlanta, Georgia. Isaiah was responsible for BellSouth’s European and Latin American operations and BellSouth’s Advertising and Publishing Company. Isaiah was also Co-Chairman of BellSouth’s Diversity Council. Before the BellSouth Enterprises role, Isaiah served three years as President of BellSouth Consumer Services, with responsibility for the strategic marketing, sales and customer service direction of BellSouth’s largest customer unit. Isaiah joined BellSouth in 1997 as BellSouth Telecommunications’ Chief Financial Officer and assumed the role of Corporate Vice President of Finance before moving to Consumer Services. A native of West Memphis, Arkansas, Isaiah holds a Bachelor of Science degree from Iowa State University and is a Certified Public Accountant. Isaiah has also completed the University of Minnesota executive MBA Program. Isaiah was nominated as NYSE 2014 Chairman of the Year and was recognized by the Outstanding Directors Exchange as a 2010 Outstanding Director.
Follow Isaiah Harris:
About : CIGNA Corporation operates as a health service company that helps people to improve the health, well-being, and peace of mind.
Edwin Kania
Managing Partner & Co-Founder; Chairman Emeritus of Flagship Pioneering
Edwin Kania is a Managing Partner and Co-Founder of Flagship Ventures and served as Chairman of the Board of Directors at Flagship Ventures between 2001 – 2014. Edwin has 33 years of experience in the venture capital industry. Prior to co-founding Flagship Ventures in 2000, Edwin spent 14 years as General Partner of OneLiberty Ventures and of its predecessor firm, Morgan, Holland Ventures. From 1983 – 1984 Edwin served as an Investment Officer at First Capital Corporation of Boston, the venture capital subsidiary of Bank of Boston and previously, as Research Associate at Harvard Business School and as General Manager at J. Cunningham, Inc. Edwin is a frequent speaker on venture capital and entrepreneurship. Edwin earned his undergraduate degree in Physics from Dartmouth College and his MBA from Harvard Business School. While at Dartmouth, Edwin was an All-American Track and Field athlete and a national and collegiate record holder. Throughout his professional career, Edwin has operated both as an investor and as an active partner to entrepreneurs in company building. Edwin’s direct investment experience covers over 100 companies. In addition, Edwin has been intimately involved in the launch and development of more than a dozen companies as the founding, lead or co-lead investor, and on occasion has assumed operating roles in support of management. Several of these companies are now publicly traded while others have been acquired by significant publicly-traded companies. The total value of the companies in which Ed has participated as founding or lead investor is currently several billion dollars. Among the companies for which Ed has served as an active Director are Acceleron Pharma (NASDAQ: XLRN), Adolor (NASDAQ: ADLR), Alere Corp. (purchased by Inverness Medical), Anesta Corp. (NASDAQ: NSTA, purchased by Cephalon), Aspect Medical (NASDAQ: ASPM, purchased by Covidien), AudioLogic (purchased by Cirrus Logic), ChemGenics Pharmaceuticals (purchased by Millennium), Cytyc Corp. (NASDAQ: CYTC), EXACT Sciences (NASDAQ: EXAS), Interactive Supercomputing (acquired by Microsoft), Ontogeny (merged into Curis, NASDAQ: CRIS), PerSeptive Biosystems (NASDAQ: PBIO, purchased by Applera), Somatogen (NASDAQ: SMTG, purchased by Baxter), and VisEn Medical (acquired by PerkinElmer). He was also a founding investor in IDEXX Laboratories (NASDAQ: IDXX) and in TripAdvisor (purchased by InterActive Corp). Currently, Edwin is a Director of Flagship portfolio companies EcoSense Lighting, Oasys Water, Selecta Biosciences, TARIS Biomedical, Tarveda Therapeutics, TransMedics and Visterra, as well as on the Board of DataCore Software. Edwin also serves on the Board of Common Impact, a non-profit organization that connects skilled professionals from global corporations to local, high potential non-profits. Edwin has been a long-time Member of the Board of Directors of MassBio, a not-for-profit organization representing theMassachusetts biopharmaceutical industry and serves as a Member of Harvard Partners’ Innovation Advisory Board and The Johns Hopkins Medicine Alliance for Science and Technology Development.
Follow Edwin Kania:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Mark Bertolini
Chairman and Chief Executive Officer of Aetna
Mark Bertolini is Chairman, Chief Executive Officer and President of Aetna, a Fortune 100 diversified health care benefits company with more than $47.2 billion in 2013 revenue. Aetna serves an estimated 44 million people with information and resources to help them make better informed decisions about their health care and has operations in North America, Asia, Europe and the Middle East. Bertolini assumed the role of CEO on November 29, 2010 and of Chairman on April 8, 2011. Bertolini joined Aetna in 2003 as head of Aetna’s Specialty Products. In July 2007, he was named president, responsible for all of Aetna’s businesses and operations across the company’s broad range of health care products and related services – including medical, pharmacy, dental, behavioral health, group life and disability plans, as well as medical management capabilities and health care management services for Medicaid plans. Prior to serving as Aetna’s president, Bertolini was executive vice president and head of Aetna’s regional businesses, which included the company’s individual, retiree, small group and middle market segments, as well as numerous product, network and service areas. Recognized as an accessible, forward-thinking and solutions-oriented leader, Bertolini is actively engaged in the national dialogue on health care reform, meeting regularly with state and federal policymakers to advocate for measures that increase access, lower costs and improve quality of health care. He is a strong advocate of market-based solutions, the expansion and use of health information technology, and the sustainability of the employer-based system. Firmly committed to diversity and inclusion, Bertolini also serves as the company’s executive sponsor for diversity, participates in several Aetna employee resource groups, and maintains a blog to communicate with employees. Among his civic activities, Bertolini serves on the Board of Directors of the U.S.-China Business Council, the Hole in the Wall Gang Camp, an organization founded by Paul Newman that serves children with cancer and other serious illnesses, and FIDELCO, an organization that breeds and trains guide dogs for the visually disabled. In 2009, he was elected the first straight ally board member of the National Gay and Lesbian Chamber of Commerce. Bertolini has been honored for his leadership by numerous universities and organizations, including the National Italian American Foundation, Outward Bound, the National Kidney Registry, Out & Equal Workplace Advocates, the Quinnipiac University Business School, and Wayne State University School of Business. Prior to joining Aetna, Bertolini held executive positions at Cigna, NYLCare Health Plans, and SelectCare, Inc., where he served as president and chief executive officer. Born and raised in Detroit, Bertolini held various jobs throughout high school and college, including assembly work at a Ford Motor Company plant and various caregiver roles in health care delivery.Bertolini is a spinal cord injury survivor and is partially disabled as the result of a severe skiing accident in 2004. In 2007, Bertolini donated a kidney to his son. His previous work and personal experiences with the health care system are foundational to his dedication to improving the patient experience and addressing the longstanding challenges facing the U.S. health care system. Bertolini holds an undergraduate degree in business administration/finance from Wayne State University and a MBA in finance from Cornell University.
Follow Mark Bertolini:
About Aetna: Aetna a diversified health care benefits company, provides individuals and many others with innovative benefits, products, and services.
Martin Dieck
Executive Chairman of Cerebrotech Medical Systems
Martin Dieck is the Chairman of Synchron & Executive Chairman of Cerebrotech Medical.
Follow Martin Dieck:
About Cerebrotech Medical Systems, ePlanet Capital, Lazarus Effect, Neurotechnology Investors, Synchron: Cerebrotech Medical Systems develops novel technologies for the non-invasive monitoring of patients after strokes and brain injuries.
Todd Dagres
Chairman and Founder of Liteboxer
Todd Dagres is the Chairman and Founder at Liteboxer.
Follow Todd Dagres:
About Liteboxer, Signpost, Spark Capital: Liteboxer is a provider of a digital fitness platform used to provide an engaging full-body boxing workout.
Jeff Arnold
Founder, Chairman & Chief Executive Officer of Sharecare
Jeff Arnold is Chairman and CEO of Sharecare, a comprehensive health and wellness engagement platform that provides people with personalized resources to help them live their healthiest lives. Arnold co-founded Sharecare in 2010 with Dr. Oz, and in partnership with Harpo Productions, Sony Pictures Television and Discovery Communications.Previously, Arnold was Chairman and CEO of HowStuffWorks.com, which he sold to Discovery Communications where he served as Chief Digital Strategy Officer, and Chief Architect of The Curiosity Project until December 2011.At 28, he founded and served as CEO of WebMD, the first healthcare company to harness the power of the Internet to empower consumers, healthcare institutions and physicians to find trustworthy medical information. In recognition of his superior achievements and contributions to the advancement of nursing and healthcare, he was inducted into the Honor Society of Nursing, Sigma Theta Tau International, as an Honorary Member. Arnold also has received honors from the World Economic Forum; the Technology Hall of Fame of Georgia; and Ernst & Young, who named him Entrepreneur of the Year, Southeast Region. Chairman of Forbes Travel Guide, Arnold also has served on numerous boards for public, private and charitable organizations.
Follow Jeff Arnold:
About Sharecare, WebMD, WebMDCorp: Sharecare is a health and wellness engagement platform providing consumers with information, programs and resources to improve their health.
Shane J Schaffer
Chairman and CEO of Cingulate Therapeutics
Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is an 18-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions of increasing responsibility at Pfizer, Novartis and Sanofi (including predecessor companies). Dr. Schaffer has broad functional and therapeutic expertise through the development and commercialization of several billion dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan® and Avapro®/Avalide®. He has led the strategic brand planning, franchise resource allocation and managed care & reimbursement strategy for numerous products. Dr. Schaffer received his Doctor of Pharmacy degree from the University of Kansas. He served as Chief Fellow and completed a Post-Doctoral Pharmaceutical Industry Fellowship at Rutgers University, College of Pharmacy in conjunction with Warner-Lambert/Parke-Davis, now Pfizer.
Follow Shane J Schaffer:
About Cingulate Therapeutics: Cingulate Therapeutics uses a unique combination of delivery technology and proven medications that creates an unmatched release profile.
James C. Katzaroff
CEO, Chairman and Founder of Vivos Inc
A serial entrepreneur who started his first company importing minerals and pewter from Brazil while in high school in southern California, Mr. Katzaroff is constantly searching for outstanding opportunities. Hired straight out of college Mr. Katzaroff was a financial consultant for Wall Street firms Bateman Eichler, Smith Barney and EFHutton. Since 1990, he has been responsible for corporate engineering, senior-level corporate strategy, fostering investment bank relationships, and has served as a senior financial advisor for numerous start-ups and development stage companies. A strong desire to make an unshakable impact in the fight against cancer led Mr. Katzaroff to found AMI in 2006.
Follow James C. Katzaroff:
About Vivos Inc: Vivos Inc develops manufacturing equipments for the production of medical isotopes used in diagnosis and treatment of diseases.
Fergus Hoban
Founder and Executive Chairman of UpStream Care
Follow Fergus Hoban:
About UpStream Care: UpStream Care is the ideal marketplace solution for medicine.
Rene Bharti
Founder & Executive Chairman of Future Fertility
Rene has held several key roles in both public and private companies, including those in the resource, technology and entertainment industry. Rene Bharti co-founded ARHT Media, along with legendary singer Paul Anka, with the aim of creating the worlds most lifelike digital humans to conduct e-commerce in a unique and viable platform. Rene Bharti holds a Bachelor of Commerce (Honors) from Queens University.
Follow Rene Bharti:
About Future Fertility, Spend: Future Fertility is a provider of artificial intelligence tools for reproductive medicine.
Edward M. Boyle
Chairman of ClearFlow
Follow Edward M. Boyle:
About ClearFlow, VenX Medical: ClearFlow is a medical device company developing technologies to solve clinical problems associated with obstructed catheters.
Howard Solomon
Chairman & CEO of Forest Laboratories
Mr. Howard Solomon has been the President of Clinical Data Inc. since April 13, 2011. Mr. Solomon has been the Non Executive Chairman and Senior Advisor of the Board of Forest Laboratories Inc. since October 1, 2013. He serves as the Chairman and Chief Executive Officer of Forest Pharmaceuticals, Inc. He began his career as an attorney at leading law firms in New York and joined Forest in 1964 as a director and secretary of the Board while serving as outside counsel for the Company. He served as the Chief Executive Officer of Forest Laboratories Inc. since 1977 until October 1, 2013, and served as its President until October 1, 2013. He serves as also served as the Chairman of Forest Laboratories Inc. He has been a Director of Forest Laboratories Inc. since 1964 and Clinical Data, Inc. since April 13, 2011. Mr. Solomon is a Trustee of the New York Presbyterian Hospital and previously served on the Board of Cold Spring Harbor Laboratories. He is a Member of the Executive Committee of the Board of Directors at the Metropolitan Opera and Chairman of its Finance Committee. He also serves on the Board of the New York City Ballet. Mr. Solomon graduated from the City College of New York and holds a J.D. from Yale University.
Follow Howard Solomon:
About Forest Laboratories: Forest Laboratories, Inc. (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships.
John Stuelpnagel
Co-Founder & Chairman of Fabric Genomics (formerly Omicia)
Dr. John Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function. John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008. Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
Follow John Stuelpnagel:
About Ariosa Diagnostics, Fabric Genomics (formerly Omicia): Global healthcare platform for genomics-driven precision medicine. Fabric’ proven AI algorithms power genomic insights.
Jeff Dachis
Founder, Chairman & CEO of One Drop
After Jeff Dachis was diagnosed with type 1 diabetes, he set out to create a data-driven digital platform that would disrupt the reactive healthcare model. In 2015, One Drop was born. The precision health company combines continuous diagnostics, predictive analytics and machine learning in an award-winning digital solution to deliver cost-saving outcomes for people worldwide living with diabetes and other chronic conditions.
Next, One Drop plans to enter the market with a daily disposable, minimally invasive continuous health sensor in development designed to provide greater flexibility and insights for people living with diabetes compared to fingersticks alone. The availability of this proprietary sensor is subject to receipt of clearance or approval from the U.S. FDA. Before One Drop, Dachis co-founded Razorfish (NASDAQ: RAZF) and led its $55MM IPO, then founded the Dachis Group (acquired by Sprinklr).
Dachis has appeared on Crain’s 40 Under 40 list and was named EY Entrepreneur of the Year. An internet pioneer, having helped create the first banner ad and web animation, Dachis now channels his passion for data, technology, and design at One Drop, building data-driven products that empower people to take charge of their health.
Follow Jeff Dachis:
About One Drop: One Drop is a diabetes management platform that helps people navigate diabetes together.
Ethan D. Leder
Co-Founder, Partner & Executive Chairman of Precision Medicine Group
Ethan Leder is the Co-Founder and Executive Chairman of Precision Medicine Group. Over the past 25 years, he has been an entrepreneur focused on building and managing innovative, market-leading companies that address critical gaps in the healthcare industry. Prior to Precision Medicine Group, Leder was the Founder and CEO of United BioSource Corporation (UBC), which became the leader in real-world research addressing safety, value, and comparative effectiveness for the life science industry. UBC was acquired by Medco Health Solutions in late 2010 and is now part of Express Scripts. Before UBC, Ethan was the Co-Founder and CEO of U.S. Bioservices, Inc., which addressed a growing need for personalized, direct-to-patient distribution of high-cost biotechnology for serious medical conditions. U.S. Bioservices was acquired by AmerisourceBergen in 2002. Prior to U.S. Bioservices, he was the Founder and President of HealthCare Financial Partners, the leading specialty lender to the healthcare industry. It was acquired by GE Capital in late 1999. Ethan received his undergraduate degree from Johns Hopkins University and his Juris Doctor from Georgetown University Law Center. He also serves on the Board of Trustees of Johns Hopkins University and is active in many charitable and community development projects in the Washington DC, metropolitan area.
Follow Ethan D. Leder:
About Precision for Medicine, Precision Medicine Group: Precision Medicine Group accelerates values and improve outcomes for innovative pharmaceutical and life science companies.
Alex Dickinson
Chairman & Co-founder of ChromaCode
Follow Alex Dickinson:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Alan Collier
Chairman & CEO of Endonovo Therapeutics
Alan Collier Chairman & Chief Executive Officer has more than twenty years of experience in corporate finance, IP development, telecommunications and technology with a concentration in healthcare and technology over the last five years. Prior to his appointment as Endonovo’s CEO and chairman, Mr. Collier served as CEO and director of IP Resources International, Inc. where he was instrumental in developing a platform for for the licensing and acquisition of life science and technology companies. Previously, Mr. Collier served as a Senior Managing Director at Mid-Market Securities, a FINRA-registered Broker-Dealer. Prior to joining Mid-Market Securities, Mr. Collier was a Managing Director at Mosaic capital and co-managed its Capital Markets Group. He was previously a Vice President at Corporate Capital Group and Managing Director and CEO of Greenbridge Capital Group. Over the progression of his career, he has specialized in the development and financing of early stage, high growth, and acquisitive companies (public and private). He has structured, participated in, and completed numerous transactions including mergers and acquisitions, equity and debt placements, capital restructuring, joint venture development, and channel partner procurement. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Mr. Collier holds FINRA Series 7, 79, 63, and 24 Licenses.
Follow Alan Collier:
About Endonovo Therapeutics, IP Resources International: Endonovo Therapeutics is a biotechnology company developing off-the-shelf regenerative products.
Gino Volpacchio
Chairman and CEO of PetVet Care Centers
Gino has extensive leadership experience in the pet care industry, and founded PetVet Care Centers in 2012. He is the consummate expert at putting together hospital acquisitions that provide maximum benefits to both sellers and buyers—every time.
Follow Gino Volpacchio:
About PetVet Care Centers: PetVet Care Centers is an operator of specialty and general practice animal hospitals in the United States.
Adriaan Ligtenberg
Founder & Chairman of SparkHealth
Follow Adriaan Ligtenberg:
About AllMobile Fund, Health2047, Pacific Technology Partners, SparkHealth, Tourmaline Labs™: SparkHealth is dedicated to bring innovations to healthcare.
Gabrielle Rios
Chairman and Chief Executive Officer of TRUINJECT
Gabrielle Rios is the founder and CEO of TRUINJECT.
Follow Gabrielle Rios:
About Stanford University Graduate School of Business, TRUINJECT: TRUINJECT™ is a software company focused on the innovation, development & commercialization of medical products for the injectable market.
David Adair
Founder & Chairman of Glenveigh Medical
C. David Adair, MD (Chairman and CSO) is a board certified maternal-fetal medicine specialist and president of Regional Obstetrical Consultants, an MFM practice with over 50 employees and offices in Chattanooga, Tennessee. Dr Adair is Professor and also serves as Vice-Chairman, Obstetrics and Gynecology, University of Tennessee College of Medicine. He has more than 50 publications and more than 20 teaching/research awards, including 4 Best Research Awards for Clinical Obstetrics. Dr Adair received his undergraduate degree in biological sciences at Morehead State University, his medical degree from Marshall University, residency in Obstetrics and Gynecology at the University of Florida Health Science Center, Jacksonville, and fellowship in Maternal-Fetal Medicine at Wake Forest University. He received extern training at Henry Ford Hospital, National Maternity Hospital, Dublin, Ireland, and at the Renal Unit Mass General Hospital.
Follow David Adair:
About Glenveigh Medical, Solas BioVentures: Glenveigh Medical is a life science and medical technology company that focuses on advancing the practice of obstetrics.
Sahaj Patel
Chairman, Co-Founder of Medly Pharmacy
Sahaj Patel is the Co-founder and Chairman of Medly. Previously, he’s managed multiple independent pharmacies in New York City
Follow Sahaj Patel:
About Medly Pharmacy: Medly Pharmacy is a digital pharmacy platform that offers free, same-day prescription delivery.
Giovanni Colella, M.D.
Co-Founder & Executive Chairman of OODA Health
Giovanni is the Executive CHairman and Co-Founder of OODA Health. Before OODA, he co-founded Castlight Health in 2008 with Todd Park and served as CEO of the company until 2017. Before co-founding Castlight, Giovanni was founder, president, and CEO of RelayHealth (acquired by McKesson in 2006), a pioneering healthcare company that provides secure digital communications to connect doctors with their patients. Giovanni has also served in senior roles at Sapient and SAI and was a consultant at the Boston Consulting Group. Before beginning his business career, he practiced medicine in Manhattan and is a board-certified psychiatrist. Giovanni graduated with an MD from the Universita Degli Studi di Milano in Italy. He completed his fellowship in public psychiatry at Columbia University, and earned his MBA from Columbia Business School.
Follow Giovanni Colella, M.D.:
About Brightline, OODA Health: OODA Health is a healthcare technology company that offers a software billing platform for providers, payers, patients, and insurers.
Robert J. Coury
Executive Chairman of Viatris
Robert J. Coury is the executive chairman of Viatris. Since 1995, when he was first hired as a strategic adviser to Mylan, Coury has held various leadership positions at the company. He is also the founder and president of the Robert J. Coury Family Foundation, a private foundation formed to give back and support his philanthropic efforts. After serving as a strategic adviser to Mylan for close to 7 years, Coury was elected to the company’s board of directors in February 2002. Soon after, he became the board’s vice chairman and was named the chief executive officer in September 2002. Coury served as CEO until January 2012 when he became the company’s executive chairman. He would stay in this role for 4 years before becoming chairman in June 2016. Under Coury’s dedicated leadership at Mylan, the company became one of the largest pharmaceutical companies in the world, with positions in both the S&P 500 and the Fortune 500 (the latter prior to the company’s reincorporation outside of the United States in 2015). Coury guided Mylan through transactions that totaled approximately $25 billion and resulted in a large portfolio of products sold in over 165 countries and territories. With a global workforce of close to 35,000, Mylan has become an international powerhouse with a high quality foundation to build upon moving forward. Most recently, Coury’s stepped up once again, being named Executive Chairman for the second time, so that he could offer the leadership needed for Mylan and Upjohn a division of Pfizer to combine and form Viatris in 2020. With its Global Healthcare Gateway™, Viatris continues to build on Coury’s vision and outstanding record of success. The company is positioned with unmatched global infrastructure and expertise. The Global Healthcare Gateway™ enables Viatris to offer opportunities to small and mid size biotech among other regional companies to quickly reach global markets leveraging Viatris’s existing infrastructure. As the executive chairman of Viatris, Coury mentors and drives the management team to execute the company’s strategy, leads the board of directors, and propels the strategic direction of the company for continued success in the global marketplace.
Follow Robert J. Coury:
About Viatris: Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Todd Goergen
Chairman of the Board of ViSalus
Todd A. Goergen joined ViSalus on August 1, 2012 as chief strategy officer. He was first appointed to the ViSalus board of directors in 2005 as a designee of RAM pursuant to its rights under its investment agreement with ViSalus. Goergen has served as Managing Member of RAM since 2001. RAM makes direct investments in small to mid-size companies. In addition, Goergen is a Managing Member of Ropart Investments, LLC, a private investment partnership. Between 1999 and 2000, Goergen was the Director of Acquisitions and Corporate Development at Blyth. Goergen has been a director of Crexendo, Inc. since November 2006 and served as Chairman of the Board from August 2007 to November 2010. Goergen is the Chairman of Digital Traffic Systems, Inc., a business consulting firm and Chairman of the Board of QCL Holdings, Inc. Goergen brings deep knowledge of our business, financial expertise and broad experience in growing and managing recently founded companies to our board. Goergen is the son of Robert B. Goergen and the brother of Robert B. Goergen, Jr. Due to his role as our chief strategy officer and his beneficial ownership of ViSalus capital stock, Goergen is not considered an independent director.
Follow Todd Goergen:
About : ViSalus is a health promoting company that created the Body by Vi 90-Day Challenge.
Vivek Kopparthi
CEO, Co-Founder & Executive Chairman of NeoLight
Vivek Kopparthi is Co-founder & CEO of NeoLight, a lean medical device start-up developing a disruptive technology to treat Jaundice in infants.
Follow Vivek Kopparthi:
About NeoLight, PriZm Therapeutics: Neolight is a medical device company that develops phototherapy beds to cure jaundice in pre-term and full term babies.
Yulun Wang
Founder, Chairman & Chief Innovation Officer of InTouch Health
Yulun Wang, Chairman, Founder & Chief Innovation Officer, InTouch Health, Inc. Dr. Wang founded InTouch Health in 2002, and served as Chairman & CEO until 2016, when he assumed the position of Chairman and Chief Innovation Officer. InTouch Health is a pioneering and market leading telehealth company that enables patients to receive clinical care from specialists at a distance. InTouch has received numerous awards including Deloitte’s Technology Fast 500 Award and Inc Magazine’s Inc 500 award as one of the fastest growing companies in America. Previous to InTouch, Dr. Wang founded Computer Motion in 1990, the company which pioneered surgical robotics. He was the principal architect and inventor of the voice-controlled robotic arm called AESOP, the first FDA-cleared surgical robot, as well as the ZEUS robotic surgical system, which performed the world’s first transatlantic surgery. Computer Motion IPO’d in 1997 and merged with Intuitive Surgical (NASD: ISRG) in 2003 for one third of the resulting company. Dr. Wang is author to more than 50 technical publications and inventor on over 100 patents.
Follow Yulun Wang:
About InTouch Health: InTouch Health is the leader in Acute Care Telemedicine solutions.
Rishi Shah
Founder & Chairman of Outcome Health
Rishi Shah is the Founder and Chairman at Outcome Health.
Follow Rishi Shah:
About Home Chef, Jumpstart Ventures, Outcome Health, Pritzker Group Venture Capital: Outcome Health delivers better health outcomes and impacts the human condition positively through technology.
Kunal Sarkar
Co-Founder & Chairman of the Board of Lumos Labs
Kunal is the CEO and Co-Founder of Lumos Labs. Prior to founding Lumosity, Kunal co-founded the private equity fund AIMLP, which manages over $400MM in capital. The fund focuses on investments in infrastructure and natural resources. Prior to founding AIMLP, Kunal was Vice President at McCown De Leeuw and Co., a $1.2 billion private equity fund making growth equity investments. Kunal started his career in the Strategic Planning and Development group at the Walt Disney Company, where he was involved in the development of Disney’s acquisition strategy and over $5 billion of M&A transactions. Kunal graduated magna cum laude from Princeton University with a B.A. in Economics and a certificate in Finance.
Follow Kunal Sarkar:
About Lumos Labs: Lumosity is a neuroscience research company that provides online brain training programs.
Daniel Burnett
Founder and Chairman of Bone Health Technologies
Dr. Burnett has a long history of biomedical device design and testing. After graduating from University of Pennsylvania’s school of Bioengineering, Dr. Burnett spent a year at the Food and Drug Administration both testing devices and writing congressional reports on the current state-of-the- art devices. Following receipt of his MD and MBA degrees from Duke University, Dr. Burnett completed his one-year internship at the Mayo Clinic in Jacksonville, FL and is currently a licensed physician in the state of California. After working for two years as a General Partner with MedVenture Associates, a medical device venture capital firm in Emeryville, CA, Dr. Burnett left the firm in 2006 and committed himself to TheraNova and its subsidiaries.
Follow Daniel Burnett:
About Ananya Health, Anathem Ventures, Bone Health Technologies, Channel Medsystems, Consano, Gravitas Medical, Perikinetics, Potrero Medical, Respirix, TheraNova LLC., University of California, San Francisco: Bone Health Technologies is developing a new standard of care for treating both osteoporosis and osteopenia, the precursor to osteoporosis.
Alex Gorsky
Chairman & CEO of Johnson & Johnson
Follow Alex Gorsky:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Karen Licitra
Group Chairman of Johnson & Johnson
Karen A. Licitra served as Corporate Vice President at Johnson & Johnson. Ms. Licitra led Worldwide Government Affairs & Policy and was responsible for Johnson & Johnson’s engagements with global government leaders at the multilateral, national and state levels. Her organization also led development of Johnson & Johnson public policy. She served as Worldwide Chairman of the Global Medical Solutions Group within Johnson & Johnson’s Medical Device and Diagnostics segment. She was responsible for establishing the strategy and vision for an $8 billion global portfolio of healthcare companies including Vision Care, Diabetes Care, Ortho Clinical Diagnostics, and Advanced Sterilization Products as well as the Computer Assisted Personalized Sedation business unit. Ms. Licitra also served as Company Group Chairman and Worldwide Franchise Chairman of Ethicon Endo-Surgery, Inc., the Minimally Invasive Surgery division of Johnson & Johnson. She was named to Fortune’s 50 Most Powerful Women in Business list in 2012. She holds a Bachelor of Science Degree in Marketing from Rider University (Formerly, Rider College).
Follow Karen Licitra:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Bruce Booth
Chairman of the Board of Kymera Therapeutics
Bruce is a Co-Founder and the Chairman of the Board at Kymera Therapeutics. He’s also a partner at Atlas Venture and focuses on the discovery and development of novel therapeutics. Since joining in 2005, Bruce has been instrumental in forming unique, innovative, and capital-efficient structures for drug discovery and development. He is a co-founder/founding investor and currently chair of the board of miRagen Therapeutics, Nimbus Therapeutics, Padlock Therapeutics, Quartet Medicine, and Rodin Therapeutics. Along with Peter Barrett, Bruce seeded, incubated, and serves on the board of Zafgen (NASDAQ: ZFGN), and Bruce is a board member of Lysosomal Therapeutics Inc. (LTI) and Unum Therapeutics. Previously, he served on the boards of past Atlas companies Avila Therapeutics (acquired by Celgene), Stromedix (acquired by Biogen), Prestwick (acquired by Biovail), and Proprius (acquired by Cypress Biosciences), among others. Previously, Bruce was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm’s private equity activities, ranging from early-stage venture capital through late-stage buyouts. Prior to Caxton, he was an associate principal at McKinsey & Company, a global strategic management consulting firm, where he advised clients on R&D productivity, corporate strategy and business development issues across the biopharmaceutical sector. Bruce currently serves as a trustee of the New York Academy of Medicine and is a term member of the council on foreign relations. He received a DPhil from Oxford University as a Marshall Scholar and a BS from the Pennsylvania State University.
Follow Bruce Booth:
About Atlas Venture, Nimbus Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Farhad Khosravi
Chairman & CEO of Imperative Care
Farhad Khosravi is the Executive Chairman and Co-Founder at Tulavi Therapeutics.
Follow Farhad Khosravi:
About Access Closure, Embolic Protection, Hotspur Technologies, Imperative Care, Imperative Care, Incept, Instylla, Ocular Therapeutix, Ostial Corporation, Tulavi Therapeutics, Tulavi Therapeutics: Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.
Jared Heyman
Chairman of CrowdMed
Jared Heyman joined Rebel Fund as Managing Partner in 2019.Jared’s sister Carly was the inspiration behind CrowdMed, after suffering for 3 years from a rare undiagnosed disease. Jared is the company’s CEO and product visionary, determining the strategic direction of the company and product. He graduated magna cum laude from the University of Texas at Austin in Business Honors and Marketing, plus the Y Combinator accelerator program. Jared is a 15-year internet tech veteran whose previous company, Infosurv, is still an active multi-million dollar success.
Follow Jared Heyman:
About CrowdMed, Infosurv, Rebel Fund: CrowdMed provides prediction market technology using the collective intelligence of ‘medical detectives’ to produce diagnostic suggestions.
Dave Firdaus
Chairman and CEO of Clever Care Health Plan Inc.
Dave Firdaus is the Chairman and CEO at Clever Care Health Plan.
Follow Dave Firdaus:
About Clever Care Health Plan Inc.: Clever Care Health Plan is a healthcare company that offers medicare advantage health plans to its members.
Frank Litvak
Chairman and CEO of Conor MedSystems
Frank Litvak, MD has been a director of the Company since March 2012. Dr. Litvack served as Chairman (from 2002) and CEO (from 2003) of Conor MedSystems, Inc., a publicly-held company focused on the development of vascular drug delivery systems, until its acquisition by Johnson & Johnson in February 2007. From 2000 to 2005, Dr. Litvack was Chairman of Savacor, Inc., a medical device company that was acquired by St. Jude Medical, Inc. in late 2005. Since 2000, Dr. Litvack has been a Professor of Medicine at University of California, Los Angeles. From 1989 until 1997, Dr. Litvack was a founder and director of Progressive Angioplasty Systems Inc., which was acquired by United States Surgical Corporation. Since 1996, Dr. Litvack has been a member of Calmedica, LLC. Since 1985, Dr. Litvack has been an attending cardiologist at Cedars-Sinai Medical Center. Dr. Litvack co-directed the Cardiovascular Intervention Center at Cedars-Sinai Medical Center from 1986 to 2000. Dr. Litvack currently serves as a director of several privately-held corporations. Dr. Litvack holds an M.D. from McGill University.
Follow Frank Litvak:
About Conor MedSystems, Entourage Medical Technologies, Pura Vida Investments: Conor Medsystems, LLC, founded in 1999, is a developer of innovative controlled vascular drug delivery technology.
Vishal Grover
Vice Chairman of CMS Group
Vishal Grover serves as the Chief Executive Officer and President of SYSTIME Computer Corporation. Mr. Grover has played a pivotal role in positioning SYSTIME as the largest JD Edwards Solutions provider in the world and moving up the value chain from being a base level Oracle Partner to a Global Oracle Platinum partner (the highest level of partnership at Oracle). He has enhanced Systime’s global footprint by entering successfully in new markets in the Americas, EMEA and APAC. Mr. Grover has also accorded high priority to Systime’s CSR activities. Prior to his leadership role at Systime, Mr. Grover served at PricewaterhouseCoopers as a management consultant. Mr. Grover serves as the Director of KPIT Global Solutions Limited. He served as Director of CMS Info Systems Private Limited. He has received a Bachelor’s Degree in Computer Engineering from the University of Michigan.
Follow Vishal Grover:
About KPIT Technologies, Music Messenger, POPxo, Twitter: Century Mechanical Systems To ensure Continued Success through the quality products, excellent service and unmatched customer care.
Moti Shniberg
Chairman & Co-founder of FDNA
Mr. Shniberg is an innovator, investor, and a serial entrepreneur. He has been key to the success of several global start-ups and businesses, especially in the sphere of innovative technologies and fast-growing web-based companies such as Face.com (acquired by Facebook). More recently, Mr. Shniberg Co-founded and is the Chairman of venture builder, Nacre Capital, specialising in AI and deep learning technologies in phenotype/genotype analysis: FDNA, world renowned company to identify rare-diseases in children (recently published in Nature Science Magazine), CyberMDX specialising in medical device cybersecurity and Seed-X, for trait recognition in agriculture. Additionally, Mr Shniberg founded MutualArt more than 10 years ago and to date it is one of the largest membership-based art information services with more than 600,000 art collectors.
Follow Moti Shniberg:
About CyberMDX, FDNA, MutualArt, Seed-X: FDNA develops facial dysmorphology novel analysis technology solutions for healthcare professionals.
Etienne Deffarges
Vice-Chairman of R1 RCM
Etienne Deffarges is an entrepreneur and part of the founding team — EVP and vice chairman of Accretive Health (now R1 RCM), a healthcare IT start-up that had its own IPO in 2010. He also holds a variety of board positions in aerospace, automotive, construction, food, energy, and healthcare. Etienne holds an MBA from the Harvard Business School, graduating as a Baker Scholar.
Follow Etienne Deffarges:
About : R1 RCM serves as a revenue cycle management partner for hospitals and healthcare systems regardless of the payment models.
Amy Schulman
Executive Chairman & Co-Founder of Lyndra Therapeutics
Amy Schulman is the Chief Executive Officer at Arsia Therapeutics since August 2014. Arsia, a biotechnology company focused on improving patients’ lives through new modes of drug delivery, and a venture partner at Polaris, a leading venture capital firm with approximately 4 billion under management in August of 2014. Amy joined Polaris Partner’s Boston office as a Healthcare Venture Partner in 2014, simultaneously assuming the role of Chief Executive Officer of Arsia Therapeutics, a Polaris-backed company. In July 2015 Amy co-founded Lyndra where she is Chief Executive Officer and President. Amy is an accomplished business leader, widely recognized for growing and stabilizing global businesses, commitment to people, strategic judgment, and efforts to advance women and promote inclusive workplace cultures. Amy joined Harvard Business School’s Faculty as a Senior Lecturer in July 2014. Prior to that, Amy led Pfizer Inc.’s $4 billion Consumer Healthcare business, which operates in 90 countries and includes well-known brands such as Advil, Centrum and Chapstick. Amy also served as Executive Vice President and General Counsel of Pfizer Inc. Key accomplishments include: revitalization of the ChapStick brand; regulatory filing for Lipitor OTC; rapid growth of Emergen-C and increased Europe profitability. Amy originally joined Pfizer in 2008 as General Counsel and saw the company through its $68 billion acquisition of Wyeth, the largest pharmaceutical acquisition in history. In 2009, Amy spearheaded an innovative approach to engaging outside counsel and became recognized as a leading voice for transforming the billable-hour model and for redefining the value of legal services. Before joining Pfizer, Amy was a Partner at DLA Piper, where she was a Member of the Board and Executive Policy Committees and built and led the international law firm’s mass tort and class-action practice handling some of the most complex legal, scientific and regulatory challenges facing the world’s largest and most reputable companies, including Kraft, Altria, Cisco, GE Healthcare and Pfizer. Amy began her career in litigation with Cleary Gottlieb Steen & Hamilton. Amy’s accomplishments have earned her accolades from leading publications and organizations. In 2013 Fortune magazine named her one of the “50 Most Powerful Women in Business.” That same year, The American Lawyer named her one of the “Top 50 Innovators,” and The National Law Journal named her one of “The 100 Most Influential Lawyers in America.” Amy also has been recognized by The American Bar Association, which honored her with the Margaret Brent Women Lawyers of Achievement award in 2012. In 2009 Forbes magazine included her on its inaugural list of “The World’s Most Powerful Women.” Amy serves on the Boards of Directors of Alnylam Pharmaceuticals, Arsanis, Biosciences, Arsia Therapeutics, BIND Therapeutics, Blue Buffalo, Lyndra, and SQZ Biotech. A Phi Beta Kappa Graduate of Wesleyan University, Amy earned her J.D. from Yale Law School in 1989.
Follow Amy Schulman:
About Arsia Therapeutics, Harvard Business School, Lyndra Therapeutics, Polaris Partners, Suono Bio: Lyndra Therapeutics is a novel technology platform reinventing medicine for a healthier world.
Miles White
Executive Chairman of the Board of Abbott
Follow Miles White:
About Abbott, Abbott, The American Academy of Arts & Sciences: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
John Sculley
Chairman and CMO, Investor of RxAdvance
John Sculley joined RxAdvance Corp as Chairman and CMO, Investor in 2015. John Sculley is a partner in Sculley Advisors LLC, a private family office founded by John Sculley and his wife, Diane Sculley. John Sculley was Chief Executive Officer of Apple Computer. John Sculley joined Apple in 1983 when the Company had $600 million in revenues; by the time he left, Apple’s revenues exceeded $8 billion. Prior to joining Apple, Sculley was CEO of Pepsi from 1973 to 1983.
Follow John Sculley:
About Misfit Wearables, RxAdvance, RxAdvance, Sculley Brothers, The Real McCoy: RxAdvance, a national full service PBM, leverages disruptive Collaborative PBM Cloud™ to manage standard & specialty drug benefits.
Joel Landau
Founder & Chairman of The Allure Group
Joel Landau is the Managing Director at Pinta Partners.
Follow Joel Landau:
About Aurora Health Network, Blueprint Health, Centers Healthcare, Claimex, Pinta Partners, The Allure Group: The Allure Group is a rapidly expanding provider of skilled nursing and rehabilitation services throughout the New York
David Silbersweig
Chairman, Dept of Psychiatry; Co-Director, Center for the Neurosciences of Brigham and Women’s Hospital
David Silbersweig, MD, is one of the pioneers of functional neuroimaging research in psychiatry. The aim of his current work in systems-level neuropathophysiology is to help provide a foundation for the development of novel, targeted, and biologically based diagnostic and therapeutic strategies to aid those suffering with mental illness. Dr. Silbersweig is now the Chairman of the Department of Psychiatry at the Brigham and Women’s/Faulkner Hospitals, and Chairman of the Brigham and Women’s Hospital Institute for the Neurosciences. He also is Stanley Cobb Professor of Psychiatry at Harvard Medical School.
Follow David Silbersweig:
About Brigham and Women’s Hospital: Brigham and Women’s Hospital is an academic medical center based in Boston, Massachusetts.
Stephen Squinto
Chairman of LyfeBulb
Stephen Squinto is the Executive Partner at OrbiMed Advisors.
Follow Stephen Squinto:
About Gennao Bio, LyfeBulb, OrbiMed, OrbiMed, Passage Bio: Lyfebulb’s mission is bridging patient communities with industry, and providing a strong voice to individuals living with chronic disease.
Paul Manning
President,Chairman & Chief Executive Officer of PBM Capital Group
Paul B. Manning has served as the chairman of our board of directors since December 2017 and as a member of our board of directors since December 2015. Mr. Manning is the Chairman and Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Prior to that, Mr. Manning founded PBM Products in 1997, a producer of infant formula and baby food, which was sold to Perrigo Corporation in 2010. Mr. Manning is a director of Dova Pharmaceuticals, Inc., a publicly traded pharmaceutical company, as well as various private companies. Mr. Manning was previously on the board of directors of Perrigo Corporation, Concordia Healthcare Corp. and AveXis, Inc. Mr. Manning received a B.S. in microbiology from the University of Massachusetts.
Follow Paul Manning:
About PBM Capital Group: PBM Capital Group is a private investment firm primarily focused on healthcare investments.
Samuel D. Waksal
Founder & Chairman of MeiraGTx
Follow Samuel D. Waksal:
About Brain-Mind Institute, Graviton, MeiraGTx, Weill Cornell Medicine: Meira Gene Therapy is a clinical-stage company developing novel treatments for inherited and acquired genetic disorders.
Allan May
Co-Founder and Chairman of Life Science Angels
Allan is a founder of Life Science Angels (www.lifescienceangels.com ), the largest angel organization in the U.S. focused solely on early stage medical device and life science start-ups, and comprised solely of high net worth individuals from the medical device or biotech fields. Since 2005, LSA has invested over $35M in 32 early stage companies, attracted in excess of $700M in contemporary or follow-on venture capital, and achieved five favorable exits. In 2011, Allan initiated the Life Science Angel Network, a syndicate of angel groups throughout the United States, which will focus on increasing the syndication and capitalization of highly vetted medical device and biotech startups. In 2007, Allan joined renowned inventor, entrepreneur and cardiac surgeon, Dr. Thomas Fogarty, in co-founding Emergent Medical Partners, a boutique venture fund focused on early stage medical device company creation and investing. EMP has made 25 investments to date with 4 successful exits, including eValve and Ardian. In 2010, Allan was elected Chairman of the Board of the Kauffman Foundation’s Angel Capital Education Foundation, now known as the Angel Resource Institute. ARI, a nonprofit devoted to the promotion and study of angel investing, works closely with the Angel Capital Association in furthering angel investing and entrepreneurial mentoring. Allan has been founder, Chair/CEO, or investor in over 50 medtech and biotech startups, including Athenagen (Comentis), Nanostim, nSpine, and BioMimedica. He lectures frequently at universities, conferences and government programs on trends and developments affecting early stage biotech and medtech investing. He co-chaired Singularity University’s Innovation and Entrepreneurship Track at its 2011 FutureMed Program, and is a member of the editorial board of Elsevier Windhover’s In Vivo magazine.
Follow Allan May:
About Angel Resource Institute, Emergent Medical Partners, FundamentalVR, Life Science Angels, Medtech Convergence Fund, Woodside Medical Management, Work Summary: Life Science Angels offers angel capital to early-stage biotech and medical device companies as a California-based company.
William C. Wortman
Director and Chairman of Exact Imaging
Mr. Wortman has been a director of Imagistx since April 2009. Mr. Wortman is presently a co-owner of Millennium Gaming. Inc. (MGI). MGI is the majority owner of Cannery Casino Resorts which owns and operates the Rampart Casino, Cannery Casino & Hotel and Eastside Cannery Casino & Hotel in Las Vegas and the Meadows Racetrack & Casino in Pennsylvania. Mr. Wortman began his career as an accountant with Laventhol & Horwath in 1974. In 1978 he joined Caesars Palace as financial controller and during the next six years, held various executive positions and though his efforts helped establish the Caesars brand as an industry leader. In 1983, Mr. Wortman purchased the Fallon Nugget and the Bonanza Inn and operated them until he sold them in 1996. In 1985, he purchased a substantial equity position in Nevada Palace in Las Vegas, a facility that was involved in a bankruptcy proceeding. Mr. Wortman, as managing partner assumed operating control restoring the facility to profitability. In 2006, Nevada Palace was sold to Cannery Casino Resorts. In addition to Imagistx, Mr. Wortman currently serves as a member of the UNLV Foundation Board of Trustees, board member of the UNLV Graduate School of Business, Board of Directors for Meadows Bank and the UNLV Leadership Campaign Committee. Mr. Wortman was the 1986 recipient of the Alumni of the Year Award for UNLV. Mr. Wortman received his Bachelor of Science in Accounting from UNLV.
Follow William C. Wortman:
About Cannery Casino Resorts LLC, Exact Imaging, Millennium Gaming. Inc: Exact Imaging is the developer of the ExactVu™ system, the first micro-ultrasound operating at 29 MHz that provides unmatched resolution.
Vicki Sato
Chairman of Vir Biotechnology
Vicki L. Sato, Ph.D., serves as chairman of the board of directors at Vir. Dr. Sato is also a professor of management practice at Harvard Business School, and an affiliate member of the Department of Molecular and Cell Biology, Harvard University. She has taught in HBS Executive Education programs and is a business advisor to enterprises in the biotechnology and pharmaceutical industries. Dr. Sato retired in 2005 from Vertex Pharmaceuticals, where she served as president since 2000, with responsibility for research and development, business and corporate development, commercial operations, legal, and finance. Prior to becoming president, she was chief scientific officer, senior vice president of research and development, and chair of the Scientific Advisory Board. Under her leadership, Vertex created a diversified pipeline of drugs. Before joining Vertex, Dr. Sato was vice president of research at Biogen, Inc., where she led research programs in the areas of inflammation, thrombosis, and HIV disease, and she participated in the executive management of the company. Several molecules from those programs have now reached the marketplace. She also served as a member of the Biogen Scientific Board. Currently, Dr. Sato is a member of the board of directors of publicly held companies Bristol Myers Squibb Company, PerkinElmer Corporation, Borg Warner Corporation, and Syros Pharmaceuticals. She also serves as chair of the board of directors for Denali. Previously, Dr. Sato has served as an overseer of the Isabella Stewart Gardner Museum. She received her A.B. from Radcliffe College, and her A.M. and Ph.D. degrees from Harvard University. Following postdoctoral work at both the University of California Berkeley and Stanford Medical Center, Dr. Sato was appointed to the faculty of Harvard University, where she was an assistant and associate professor of biology.
Follow Vicki Sato:
About : Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Nitin Nanda
CEO,Founder & Chairman of Aligned TeleHealth
Dr. Nitin Nanda, founder of Aligned Telehealth, is a respected physician, entrepreneur, leader, and educator. Since founding the Company in 2000, Dr. Nanda has grown Aligned Telehealth into one of the largest behavioral health specialty practices in the US. He built a successful practice model based on clinical expertise, compassion, operational efficiency and fiscal responsibility. He is Assistant Clinical Professor at the UCLA David Geffen School of Medicine and Clinical Assistant Professor in Medicine at the USC Keck School of Medicine. Dr. Nanda is Chief of Psychiatry and Behavioral Health at the Los Angeles Jewish Home. He also serves as Medical Director of the Lisa and Ernest Auerbach Geriatric Psychiatry Unit at the Joyce Eisenberg-Keefer Medical Center in Los Angeles. Dr. Nanda obtained his medical training in India and served briefly in Africa, where he worked with community hospital and clinics, caring for the very ill and underserved. He then joined UCSF School of Medicine’s Clinical Research department. Later, Dr. Nanda completed an Internship and Residency at the UCLA David Geffen School of Medicine, where he was nominated Chief Resident. With a deep interest and passion in caring for seniors, Dr. Nanda pursued a Geriatric Psychiatry Fellowship at UCLA.
Follow Nitin Nanda:
About Aligned TeleHealth, Amwell: Aligned Telehealth is a provider of a SaaS-based platform used to offer telemedicine and healthcare management services.
Alex Jimenez-Ness
Founder and Executive Chairman of Welwaze
Alex Jimenez-Ness is an entrepreneur with a strong passion for a humanistic approach to technology and science. Originally from Spain, Alex has dedicated over 20 years to build his career in private equity in the U.S., after starting his career in private banking in Europe.Alex founded Sofos Capital, a multifamily office wealth advisory group, Domus One Group, a private equity platform for real estate developments, and One Eleven Capital, a private equity firm managing capital across selected asset classes, which consequently led him to found and spearhead Welwaze Medical.The recession in 2008 brought a great deal of personal growth and Alex shifted his investment strategy focusing on companies and opportunities that have a strong social impact while creating value and return to his investors and shareholders.Alex is a early stage investor in technology startups and currently sits on the Board of three family groups. He is invited to speak to groups looking for inspiration, purpose, and growth.His continuous support to Miami’s community has earned him recognition as a Miami-Dade County Key recipient
Follow Alex Jimenez-Ness:
About Welwaze: Welwaze develop tools to empower people to manage their health, and improve the way they live.
Lixiao Wang
Founder, Chairman, and Board of Directors of Urotronic
Lixiao Wang is the Founder, Chairman, and Board of Directors of Urotronic, Inc.
Follow Lixiao Wang:
About Urotronic: A Minnesota based, medical device company, making an exciting innovation in urethral stricture treatment.
Maurice Ferre, M.D.
CEO & Chairman of InSightec
Dr. Maurice R. Ferré was the founding President and Chief Executive Officer of MAKO Surgical Corp, serving from 2004 until the acquisition of the company by Stryker Corp. for $1.7 billion in 2014. In June 2007, Dr. Ferré received the Ernst & Young Entrepreneur of the Year 2007 award for emerging companies in Florida. In 1993, he founded Visualization Technology, Inc., a medical device company for image-guided surgery, where he served as Chief Executive Officer until 2002 when the company was acquired by GE Healthcare, the healthcare division of the General Electric Company. Dr. Ferré served as Vice President of Strategic Development for GE Navigation, a Division of GE Healthcare, until 2004. Dr. Ferré holds an M.D. and a Master’s degree in Public Health from Boston University.
Follow Maurice Ferre, M.D.:
About DermaSensor, InSightec: InSightec develops and manufactures MR-guided Focused Ultrasound technology devices for image-guided acoustic surgery.
Brent Shafer
Chairman & CEO of Cerner
As chairman of the board of directors and chief executive officer of Cerner, Brent Shafer focuses on growing and expanding Cerner’s market-oriented business units, consumer brand, key strategic relationships and priority corporate initiatives. Previously chief executive officer of Philips North America, Shafer oversaw a health technology portfolio that included a broad range of solutions and services covering patient monitoring, imaging, clinical informatics, sleep and respiratory care as well as a group of market-leading consumer-oriented brands. Shafer also was previously the chief executive officer of the global Philips Home Healthcare Solutions business. Shafer has extensive experience driving value-based business models from a foundation of innovation. He has helped lead the growth of a complex multinational organization over a number of years in senior leadership positions with Philips. He has also served in senior leadership positions at other companies, including GE Medical Systems, Hill-Rom and Hewlett-Packard. Shafer started his career at Intermountain Healthcare’s Primary Children’s Hospital. He serves on the board of No Barriers USA, a nonprofit that organizes life-changing experiences for youth, veterans and people with disabilities. Shafer is also active in the Health Management Academy, a community of executives from the largest U.S. integrated health systems and most innovative health care companies. He has a bachelor’s degree from the University of Utah.
Follow Brent Shafer:
About Cerner, Philips: Cerner is a supplier of healthcare information technology solutions, services, devices, and hardware.
Stephen Kaldor
Co-Founder and Chairman of XinThera
Steve is a Venture Partner with Versant Ventures and is also the CEO of Quanticel Pharmaceuticals, a privately held Versant portfolio company focused on cancer drug discovery. Steve was CEO of Ambrx from 2007-2010 and helped this biologics company mature its drug portfolio and platform through deals with Pfizer, Merck, Lilly, and Merck-Serono. Steve served as President & CSO of Syrrx from 2002-2005, and led the company through its $270M acquisition by Takeda in 2005 and for several years post acquisition. Prior to joining Syrrx, Steve gained 12 years of R&D experience at Eli Lilly as both a researcher and Director. A chemist by training, Steve is a co-inventor of ten therapeutic compounds that have entered the clinic including Viracept, a marketed AIDS medication, and Nesina, a marketed diabetes medication. Steve also serves as an independent board member for various companies including Furiex (2010 – current), Amira (2008 through 2011 acquisition by BMS) and Anaphore (2008 – 2011). He received a PhD from Harvard University and a BA from Columbia University.
Follow Stephen Kaldor:
About XinThera: XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
John Heil
Co-Founder, Chairman and CEO of Imalogix
Follow John Heil:
About iFusionLabs, Imalogix: Imalogix assists hospitals and imaging centers by transforming imaging data into actionable information to improve patients’ safety.
Edward Ludwig
Non-Executive Chairman of the Board of Directors of POCARED Diagnostics
Edward Ludwig has been a Member of the Board of Directors of Boston Scientific since March 2014. Edward is the former Chairman of the Board of Directors of Becton, Dickinson and Company (“BDX”), a global medical technology company, having served in that position from February 2002 through June 2012. Edward also served as BDX’s Chief Executive Officer from January 2000 to September 2011 and as its President from May 1999 to December 2008. Edward joined BDX as a Senior Financial Analyst in 1979. Prior to joining BDX, Edward served as a Senior Auditor with Coopers and Lybrand (now PricewaterhouseCoopers) where he earned his CPA and as a financial and strategic analyst at Kidde, Inc. Edward serves as Lead Director on Aetna Inc.’s Board of Directors and chairs its Finance Committee and is a Member of the Board of Directors of Xylem, Inc. Edward serves as the Non-Executive Chairman of POCARED, a privately held firm in Israel. Edward is also a Member of the Board of The Center for Higher Ambition Leadership, which is dedicated to studying, documenting and advancing the principals of Higher Ambition Leadership that drive the most successful enterprises in terms of longer term shared value creation. Edward served as a Member of the Board of Trustees of the College of the Holy Cross (2005-2013), and the Columbia Business School Board of Overseers (2010-2015). Edward also served as a Member of the Board of Trustees of the Hackensack University Medical Center Network Board of Trustees. Edward received a B.A. degree in Economics and Accounting from The College of the Holy Cross and a MBA degree from Columbia University.
Follow Edward Ludwig:
About : Revolutionizing infections disease practice with culture-free microbiology.
Peter Soderberg
Chairman Of The Board and Investor of ABM Respiratory Care
Chairman Of The Board and Investor at ABM Respiratory Care.
Follow Peter Soderberg:
About ABM Respiratory Care, Tactile Medical, Worthy Venture Resources, LLC: ABM Respiratory Care is a medical device startup that develops ventilation solutions for people suffering from pulmonary diseases.
Elizabeth Pattullo
Chairman and Founder of Beacon Health Strategies
Elizabeth Pattullo, one of Beacon’s founders, is responsible for all strategic and business development activities. Creating the business concept of delivering client-focused, cost effective behavioral health services, Ms. Pattullo has grown Beacon into a company that manages more than seven million members in 14 states. Having lectured at both the Heller School at Brandeis University and Harvard University Medical School, Ms. Pattullo has more than 30 years of public and private sector management experience in complex and highly-charged environments. As executive director for Mental Health Management of America (MHMA), she administered the first and largest carve-out of mental health and substance use disorder services for Medicaid enrolled clients in the country. Under her leadership, MHMA improved treatment outcomes while reducing overall costs by $50 million. Ms. Pattullo earned her M.Ed. from Harvard University.
Follow Elizabeth Pattullo:
About Beacon Health Strategies: Beacon Health Strategies is engaged in the development and management of mental health and substance abuse programs for hospitals.
Tony Coles
Chairman and CEO of Yumanity Therapeutics
Anthony Coles was named Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, in October 2014. Prior to this, from October 2013, Anthony Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately-held company. Anthony Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company (“Onyx”), from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer and a member of the board of directors of NPS Pharmaceuticals, Inc., a public biopharmaceutical company (“NPS”). Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Anthony Coles has been a director of the Company since April 2014. He is a member of the Compensation Committee and the Finance Committee.
Follow Tony Coles:
About Yumanity Therapeutics: Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases caused by protein misfolding.
Tim Koogle
Investor, Board member, and Chairman of Cadence Health Inc
Tim Koogle joined Cadence Health as Investor, Board member, and Chairman in 2017.
Follow Tim Koogle:
About Cadence Health Inc, ecover, eCoverage, Olly Ltd, Serendipity Land Holdings, LLC, The Koogle Foundation, True Botanicals: Cadence Health is a consulting company bringing Industrial and System Engineering tools to complex health systems.
Jonathan Lim
Chairman & Co-Founder of Boundless Bio
Jonathan Lim is Founder of Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company that is a portfolio company of City Hill Ventures, LLC, a health care investment firm that he founded in 2010. Jonathan is also a Board Director of Bionomics Ltd (ASX: BNO). Prior to Ignyta, Jonathan’s experience includes Chairman, CEO and co-founder of Eclipse Therapeutics, Inc.; President and CEO of Halozyme Therapeutics, Inc. (Nasdaq: HALO); management consultant at McKinsey; NIH Postdoctoral Fellow at Harvard Medical School; and general surgery resident at New York Hospital-Cornell. In addition to serving on the Bio-X Advisory Council, Jonathan has been actively involved with his class reunion campaigns and other Stanford related activities. Jonathan has a B.S and M.S. from Stanford in Biological Sciences, an M.D. from McGill University and an M.P.H. from Harvard. Jonathan lives in San Diego with his wife, Dr. Conyee Tsai Lim (BA ’93), and their three children.
Follow Jonathan Lim:
About ARCH Venture Partners, Boundless Bio, City Hill Ventures, Erasca: Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Charles D. Lake II
President, Aflac International; Chairman, Aflac Japan of Aflac
Charles Lake is president of Aflac International and chairman of Aflac Japan. Lake joined Aflac International in February 1999 and Aflac Japan in June 1999. He became deputy president in 2001, president in 2003, vice chairman in 2005 and chairman in 2008. In 2014, he also assumed the position of president, Aflac International. Before joining Aflac, Lake practiced law in Washington, D.C. He also served as director of Japan affairs and special counsel at the office of the U.S. Trade Representative in the Executive Office of the President. Lake currently serves as a director on the board of the Japan Exchange Group, Inc.; the Peterson Institute for International Economics; the Coalition of Service Industries; and the U.S.-Japan Business Council. He is also president emeritus of the American Chamber of Commerce in Japan (ACCJ). Lake received a Bachelor of Arts in Asian studies and political science from the University of Hawaii at Manoa and a Juris Doctor from the George Washington University School of Law.
Follow Charles D. Lake II:
About Aflac: Aflac is a company that offers individuals and companies supplemental disability insurance.
Dean Travers
Co-Founder & Chairman of Luminopia
Dean Travers is the Co-Founder & CEO at Odin.
Follow Dean Travers:
About Luminopia, Odin: Luminopia is pioneering a new class of treatments for significant neuro-visual disorders.
Michael Lin
Co-Founder & Executive Chairman of Reify Health
Michael Lin is the Co-Founder & Executive Chairman at Reify Health.
Follow Michael Lin:
About Reify Health: Reify Health is a cloud-based software company that develops tools for the clinical trial ecosystem.
James Sapirstein
Chairman, CEO and President of First Wave BioPharma
Mr. Sapirstein is a start-up and turnaround specialist with 30 years of pharmaceutical and biotechnology industry experience. Most recently, he served in key leadership positions at Gilead Sciences, Serono Laboratories, and Tobira Therapeutics. Beginning in 2000, Mr. Sapirstein led and developed the global marketing strategy for Gilead’s flagship HIV drug Viread. He played an instrumental role in the development of the drug combination strategy that resulted in Gilead’s acquisition of Triangle’s nucleoside portfolio. In 2002, he accepted the position of Executive Vice President for Serono Laboratories where he led a team of over 100 professionals to rebuild a struggling HIV and pediatric growth hormone business. In this role, he increased sales of Serono’s products several fold, while forging the U.S. commercialization of Serostim and Saizen. As CEO of privately held Tobira Therapeutics, a New Jersey-based biopharmaceutical company focused on the development of novel HIV and infectious disease compounds, he was instrumental in helping to raise over $60 million in venture capital and research funding. Mr. Sapirstein is a graduate of the Rutgers University Ernest Mario School of Pharmacy and recieved an MBA from Fairleigh Dickinson University.
Follow James Sapirstein:
About First Wave BioPharma, Hepion Pharmaceuticals: First Wave BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies.
Matthew Emmens
Chairman of the Board of Director of Vertex Pharmaceuticals
Matthew was appointed Chairman on June 18, 2008 and has been a member of the Board since March 12, 2003.He is also a member of the Nomination Committee. He was the Company’s Chief Executive Officer from March 2003 to June 2008.Matthew brings to the Board his operational knowledge of Shire and his wealth of international sales, marketing, integration and operational experience in the pharmaceutical sector. Matthew is a Director of Vertex Pharmaceuticals Inc.He served as Chairman, CEO and President of Vertex Pharmaceuticals Inc. from 2009 until early 2012 and is a former Director of Incyte Corporation.
Follow Matthew Emmens:
About : Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Gregory A. Demopulos
Chairman and Chief Executive Officer of Omeros
Gregory A. Demopulos, M.D. is one of our founders and has served as our President, Chief Executive Officer and Chairman of the Board of Directors since June 1994. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training at Duke University. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.
Follow Gregory A. Demopulos:
About Omeros: Omeros is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.
Deepak Chopra
Chairman, Founder & Director of The Chopra Foundation
Founder of The Chopra Foundation, a non-profit entity for research on well-being and humanitarianism, and Chopra Global, a whole health company at the intersection of science and spirituality, is a world-renowned pioneer in integrative medicine and personal transformation. Chopra is a Clinical Professor of Family Medicine and Public Health at the University of California, San Diego and serves as a senior scientist with Gallup Organization.
Follow Deepak Chopra:
About Chopra Global, Osi Systems, The Chopra Foundation: The mission of the Chopra Foundation is to advance the cause of mind/body spiritual healing, education, and research.
Guy Miller
Chairman, CEO & Co-Founder of Edison Pharmaceuticals
Guy Miller, MD, PhD is the co-founder of Edison Pharmaceuticals, and has served as Chairman and Chief Executive Officer of the Board since 2005. Prior to founding Edison, he founded Galileo Pharmaceuticals, a biopharmaceutical company, and was its Chairman and CEO from 1995-2005. Dr. Miller holds an MD from the Medical College of Pennsylvania and a PhD in chemistry from the University of Virginia. He completed his surgical internship at the University of Chicago, and a residency in anesthesiology and critical care medicine at Johns Hopkins. Dr. Miller completed a fellowship in multidisciplinary critical care medicine at Johns Hopkins, where he was on the faculty as an Assistant Professor until 1996. He is currently an attending physician in medical-surgical critical care medicine at Stanford University-PAVAMC.
Follow Guy Miller:
About Ampere Life Sciences, BioElectron Technology Corporation, Edison Pharmaceuticals, Stanford University School of Medicine: Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Roger Fine
Co-Founder & Chairman; Chairman of the Robert Wood Johnson Foundation of Windham Venture Partners
Follow Roger Fine:
About Windham Venture Partners: Founded in 2006, Windham is a New York City based venture capital firm focused on healthcare, with a particular emphasis on medical
Victor Perlroth
Chairman & CEO of Kodiak Sciences
Victor Perlroth co-founded Kodiak Sciences in 2009 and is the company’s Chairman and Chief Executive Officer. Together with a talented core team, he has built Kodiak on a foundation of scientific excellence with a simple mission—to design and develop novel medicines for highly prevalent diseases. Under Perlroth’s leadership, Kodiak is building a pipeline of potentially life transforming ophthalmology drug candidates. Previously, Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003, Perlroth co-founded Avidia, a biopharmaceuticals drug discovery and development company where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management responsibility across both corporate and research and development activities. Perlroth was one of two principals involved in the acquisition of the company by Amgen for $450 million. Earlier, Perlroth worked at Guzik Technical Enterprises, the industry-leading provider of test equipment to the hard disk drive industry, where he was Chief Operating Officer. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology summa cum laude from Princeton University.
Follow Victor Perlroth:
About Kodiak Sciences: Kodiak is designing and developing novel therapies for the treatment of retinal disease.
Michael Zamagias
Chairman & Chief Executive Officer of TeleTracking
Michael Zamagias is the majority owner of TeleTracking and is responsible for all business operations of the company. His involvement with TeleTracking began in 1991 when the company was in its earliest phase as a start-up. Since then, TeleTracking has grown the niche it created into a multi-million dollar annual business that is now the recognized world leader in capacity management automation solutions for healthcare organizations. A perennial KLAS category leader, TeleTracking has grown by over 500 percent in the past decade and holds an 80 percent share of the penetrated capacity management market, with 2,000 applications in nearly 900 hospitals around the world. Clients include most of the nation’s top hospitals, as recognized by U.S. News and World Report, Thomson-Reuters and Becker’s Hospital Review. His entrepreneurial acumen has produced a successful network of businesses in addition to healthcare technology, including commercial real estate development, leasing and property management, banking/finance and energy development. Mr. Zamagias entered the real estate business in his early twenties as a licensed residential salesperson. He soon moved into the commercial real estate business, establishing himself as a top commercial leasing agent. In 1984, Mr. Zamagias moved to Pittsburgh, and founded his own company that, in 1987, became Zamagias Properties. Mr. Zamagias now owns a controlling interest in more that 1.6 million square feet of office, retail, and mixed-use properties located primarily in Western Pennsylvania. He co-founded Pennsylvania Capital Bank in 1991 (later to become part of Huntington Bank) and has developed over 150 oil and gas wells in Pennsylvania. In 2011, he purchased a fast-casual, wood-fired, pizza and sandwich concept called City Oven in order to create a business that would employ and mentor entrepreneurial teens and adults from underprivileged backgrounds. City Oven is located in Mr. Zamagias’ Times Building in Downtown Pittsburgh.
Follow Michael Zamagias:
About TeleTracking: TeleTracking Passionate About Optimizing Hospital Operations & PatientFlow.
Aaron Greenblatt
Chairman of Flipt RX
Years in Pharmaceutical Industry: 4 Areas of Specialty & Work History: Aaron completed his undergraduate studies at University of Maryland College Park, and received his PharmD from University of Maryland School of Pharmacy. Aaron rotated through several departments in G&W during various summer internships throughout high school and college. Aaron formally joined G&W full-time in 2009 as the head of Supply Chain. After building the newly formed Supply Chain department at G&W, Aaron also ran the packaging department before moving into his role as Director of Sales, Business development, and company culture. Aaron currently focuses on developing new growth opportunities for G&W while deepening customer relationships, and ensuring that G&W attracts and retains employees that are aligned with its core values. Aaron is passionate about entrepreneurship, company culture and core values, leadership, personal growth, team building, impact, and building new relationships. Areas of interests include; Supply Chain, Efficiency, Customer relationships, Organizational Development, Business Strategy and Development, and building a culture of sustainable growth. Aaron has taken the opportunity to direct these passions towards the growth and continuous evolution of G&W Laboratories. Hobbies and Family: Aaron enjoys reading (especially at the beach), going to concerts, windsurfing, golf, traveling and playing basketball. He is also a food and wine enthusiast, a loyal fan of the NY Yankees, the NY Giants, and recently got engaged.
Follow Aaron Greenblatt:
About Flipt RX, G&W Laboratories: Flipt RX manages pharmacy benefits.
David M. Geliebter
Executive Chairman & Co-Founder of Remedy Pharmaceuticals
David is a co-founder of Remedy Pharmaceuticals. A serial entrepreneur, he has over 50 years of experience successfully starting and growing several businesses. David founded and ran the Carson Group, a global financial information and advisory company, which was sold to Thomson Corporation in 2000. He was also a founding principal and President of Evolution Capital, a healthcare investment banking firm. Prior to that, David founded Harvard Capital, a financial communications company that was acquired by WPP Group in 1986. David is the Managing Partner of Carrot Capital Healthcare Ventures and founder and board member of Critical Diagnostics, a diagnostics company focused on cardiac disease. David is a past winner of the Ernst & Young Entrepreneur of the Year Award.
Follow David M. Geliebter:
About Critical Diagnostics, Embark Healthcare, Flat Squirrel Press, Learmont Pharmaceuticals, Martin Pharmaceuticals, Remedy Pharmaceuticals, Woolsey Pharmaceuticals: Remedy Pharmaceuticals is a clinical stage pharmaceutical company that develops molecule drugs for acute central nervous system disorders.
J. Kurt Jacobus
Chairman and CEO of Restor3d
Kurt Jacobus is a Managing Director of the GRA Venture Fund.
Follow J. Kurt Jacobus:
About Restor3d: Restor3d offers surgeons with biomaterials, 3D printing technologies, and artificial intelligence to repair and rebuild the human body.
Allan Camaisa
Chairman, CEO, and Founder of Calidi Biotherapeutics
Allan Camaisa is a serial entrepreneur, investor, and technologist, with proven leadership skills in bootstrapping start-ups. He has had four successful exits, which were sold to publicly traded Fortune 1000 companies with tremendous shareholder returns. Since taking over as Chairman and CEO of Calidi Biotherapeutics, he has made a number of advancements, including a partnership with the U.S. NIH, recruitment of a Scientific Advisory Board, and the engagement of license negotiations with large pharmaceutical organizations, among others. Several years ago, Mr. Camaisa lost his own father to cancer; a tragedy that inspired him to co-found Calidi and make it his personal mission to bring to market a cure for difficult-to-treat cancers. Previously, Mr. Camaisa was the CEO and Chairman of Parallel6, Inc., a creator of a digital mobile software platform that engaged clinical trial participants and powered the enrollment, management, and retention of those participants on behalf of pharmaceutical organizations. Parallel6 was sold to PRA Health Sciences in 2017. Their clients included Sanofi, STSI/Genentech, Johnson & Johnson/Janssen, Abbott/Abbvie, PPD, PRA Health, Pfizer, Roche, and the NIH, among others. In 2005, Mr. Camaisa founded Anakam, Inc., a software security company that pioneered and patented SMS two-factor authentication, focused on healthcare, government, banking, and e-commerce, which safeguarded digital records and infotmation through a platform that delivered government-level multifactor authentication and security. Anakam sold a global license to the Veterans Administration (VA) to secure access to the VA’s primary patient portal called My HealtheVet. Other notable Anakam clients included the Center for Medicare and Medicaid, the Department of Homeland Security and several medical device companies including Boston Scientific and EntraHealth. Anakam was recognized by INC 500 as one of the fastest growing companies in the U.S. and was acquired by Equifax in 2010. Prior to Anakam, Mr. Camaisa founded High Technology Solutions (HTS) in the early 1990’s, a software systems integrator that he grew from two people to more than 500 employees and $50 million in revenue. Under his lead, HTS also developed and patented many technologies such as online car configuration, touchscreen kiosks, an online food delivery and ordering service. HTS was recognized as an INC 500 company three years in a row and was sold to Wireless Facilities, Inc. (now Kratos Defense) in 2004. Before entering business, Mr. Camaisa served eight years as a surface warfare officer in the United States Navy. He currently owns seven U.S. patents and has received many personal awards including the Deloitte FAST 50, the Governor’s Small Business of the Year Award and the Ernst and Young Regional Entrepreneur of the Year. He also received awards from the San Diego Asian Business Association, Tech America, and the U.S. Small Business Association, which honored him as Small Business Person of the Year. He is a graduate of both the United States Naval Academy and the prestigious Owners Management Program at Harvard Business School. Mr. Camaisa serves as a member of the YPO (Young Presidents Organization) San Diego Coastal Chapter. He also participated on several other volunteer boards including the United Way of San Diego, and Opportunity International (Micro-Enterprise Loans to the Poor).
Follow Allan Camaisa:
About Calidi Biotherapeutics: Calidi Biotherapeutics is a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer.
Ross A. Jaffe
Co-Founder and Chairman of Faro Health
Ross Jaffe is the Co-Founder and Chairman at Faro Health.
Follow Ross A. Jaffe:
About Faro Health, Versant Ventures, Vital Therapies: Faro Health is a company that handles the tedious work better left for a computer.
Brad Bostic
Founder, Chairman & CEO of hc1
Brad Bostic has been founding, leading, and investing in high-growth technology companies for the past 25 years. Frustrated by the prevalence of one-size-fits-all, trial and error patient care, Brad founded hc1 to save lives, save money, and eliminate wasteful practices with precision health insights that empower patients, providers, and health plans to make tailored care decisions. Today, the hc1 Platform analyzes billions of live data points across 20,000 provider locations to personalize care, improve outcomes, and eliminate waste for tens of millions of patients each year. By transforming lab and prescription data into personalized healthcare insights with cloud computing and machine learning, hc1 is the leader in critical insights, analytics, and solutions for precision health. Brad is among the top innovators in healthcare according to Becker’s Healthcare and was recognized as the 2020 Dynamic Leader of the Year by the Indiana Chamber of Commerce.
Follow Brad Bostic:
About hc1, Health Cloud Capital: Hc1 enables real-time lab stewardship and precision prescribing for health systems, laboratories and physicians.
John Mazziotta
Chairman, Department of Neurology of UCLA Health System
Follow John Mazziotta:
About UCLA Health System: UCLA Health has provided the best in healthcare and the latest in medical technology to the people of Los Angeles and throughout the world.
Ron Zwanziger
Co-Founder, Chief Executive Officer, Chairman, and Director of LumiraDx
Ron Zwanziger, a strategic visionary and entrepreneur, is the CEO of LumiraDx, which he co-founded in 2014. He previously founded and led numerous successful diagnostic firms, including Alere, Inverness Medical Technology (which was acquired by Johnson & Johnson in 2001), and MediSense, the first company to introduce an electrochemical glucose sector. He currently serves on the Board of Directors of several private companies.
Follow Ron Zwanziger:
About LumiraDx: LumiraDx is a healthcare company that manufactures a diagnostic platform to support a menu of tests with lab comparable performance.
Mark C Miller
Executive Chairman of Stericycle
Mark C. Miller has served as our Chairman of the Board since May 2016 and as a director since May 1992. He became our Chief Executive Officer in May 1992, a position he held until January 2013, and became Chairman of the Board in August 2008, a position held until January 2013 when he became Executive Chairman of the Board. From May 1989 until joining us, Miller served as vice president for the Pacific, Asia and Africa in the international division of Abbott Laboratories, a diversified health care company, which he joined in 1976 and where he held a number of management and marketing positions. Miller serves as a director of Accelerate Diagnostics, Inc., a developer of automated diagnostics systems, and formerly served as a director of Ventana Medical Systems, Inc., a developer and supplier of automated diagnostic systems. He received a B.S. degree in computer science from Purdue University, where he graduated Phi Beta Kappa. Miller was selected by Morningstar, Inc. as its “2009 CEO of the Year.”
Follow Mark C Miller:
About Stericycle: Stericycle provides solutions that protect people and brands, promote health, and safeguard the environment.
Martin Rash
Chairman of the Board of Directors of RCCH HealthCare Partners
Martin Rash is Executive Chairman of RCCH Healthcare Partners. Prior to the forming of RCCH, Martin was Chairman and CEO of RegionalCare Hospital Partners. Martin has also served as Chairman and CEO of Province Healthcare, a $1 billion NYSE company that owned 21 hospitals and managed more than 50 facilities. Prior to his tenure at Province Healthcare, Martin served as Executive Vice President and Chief Operating Officer for Community Health Systems where he led the growth of the company from 10 to 41 hospitals in 17 states. Earlier in his 25-year healthcare career, Martin worked at numerous community hospitals in various executive, administrative, and financial roles. Martin’s experience and leadership includes membership on the development team of the largest hospice company in the country and a long-term board seat on the largest Medicare Advantage program in the United States. Martin is a past chairman and one of the co-founders of the Federation of American Hospitals and has also previously served as Chairman of the Nashville Healthcare Council. Martin Rash holds both a bachelor’s and MBA from Middle Tennessee State University.
Follow Martin Rash:
About RCCH HealthCare Partners: RCCH HealthCare Partners provides healthcare services.
Jeffrey Port
Co-Founder & Chairman of Angiocrine Bioscience
Jeffrey Port is the Founder of Angiocrine Bioscience, Inc.
Follow Jeffrey Port:
About Angiocrine Bioscience, RF Surgical Systems, TMRW Life Sciences, Weill Cornell Medicine, Weill Cornell Medicine: Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
Daniel P. McCartney
Chairman & CEO of Healthcare Services Group
Follow Daniel P. McCartney:
About Healthcare Services Group: Healthcare Services Group provides professional management of ancillary services to a wide range of clients.
Richard J Stephenson
Founder and Chairman of the Board of Cancer Treatment Centers of America
Follow Richard J Stephenson:
About Cancer Treatment Centers of America, Gateway for Cancer Research, International Capital & Management Company, Sheridan Capital Partners: CTCA has been helping patients win the fight against cancer using advanced technology and a personalized approach.
Britt Newhouse
Chairman of Guy Carpenter & Company
Britt Newhouse is Chairman of Guy Carpenter & Company, LLC and a member of the Board of Managers. From 2001 until his appointment to Chairman in 2008, Mr. Newhouse served as the President and CEO of the firm’s Americas operations, where he was responsible for all broking business in the United States, Canada, Latin America and the Caribbean. Mr. Newhouse also held the position of Eastern Region Manager and served as the New York Branch Manager. He currently serves on both the Education Committee and on the Board of Overseers for St. John’s University, School of Risk Management, Insurance and Actuarial Science. He is also a member of the Brokers and Reinsurance Markets Association (BRMA) board of directors.
Follow Britt Newhouse:
About Guy Carpenter & Company: Guy Carpenter & Company, LLC operates as a reinsurance intermediary. The company offers accident and health, agriculture, alternative risk
Eirini Schlosser
Chairman & CEO of Dyania Health
Follow Eirini Schlosser:
About Dyania Health, MedicusData.AI: Dyania Health develops a research platform for pharma companies and hospital systems.
Rocco Ortenzio
Vice Chairman and Co-Founder of Select Medical
Rocco A. Ortenzio, a co-founder of the Company and a member of its Board of Directors since February 2005, has served as the Company’s Vice Chairman and Co-Founder since January 2014. He served as the Company’s Executive Chairman since February 2005. In 1997, Mr. Ortenzio co-founded and served as a member of the Board of Directors of the Company’s subsidiary, Select Medical Corporation (“SMC”). He served as the Executive Chairman of SMC from September 2001 to February 2005, and as its Chairman and Chief Executive Officer from February 1997 to September 2001. In 1986, he co-founded Continental Medical Systems, Inc., a provider of comprehensive medical rehabilitation services, and served as its Chairman and Chief Executive Officer until July 1995, when it merged with Horizon Healthcare Corporation. In 1979, Mr. Ortenzio founded Rehab Hospital Services Corporation, a hospital chain acquired by National Medical Enterprises, Inc. (now called Tenet Healthcare Corporation) in January 1985, and served as its Chairman and Chief Executive Officer until June 1986. In 1969, Mr. Ortenzio founded Rehab Corporation and served as its Chairman and Chief Executive Officer until 1974, when it merged with American Sterilizer Company. From 1996 to 1999, he served on the Board of Governors of the Pennsylvania State System of Higher Education. Mr. Ortenzio serves as a Director of Quorum Health Group, Inc., and is a fund advisor to HLM Partners Inc., a venture capital firm located in Boston, Massachusetts, and Dauphin Capital Partners, a venture capital fund located in Locust Valley, New York.
Follow Rocco Ortenzio:
About Select Medical: Select Medical treats approximately 30,000 patients in a typical day.
Larry Papasan
Chairman of the Board of Directors of MEDOVEX
Larry Papasan is the retired President of Smith & Nephew Orthopedics. Larry joined Smith & Nephew in July, 1991 as President of the Ortho Division and retired December 31, 2002. During this 11-1/2 year period, the Division grew in sales from $300 million to $650 million while growing profitability at over 15% per year. Smith & Nephew Orthopedics is a company with manufacturing in Memphis and Germany. Larry was responsible for Research and Development, Manufacturing, Marketing, Sales and all Administrative functions of the Company during his 11-1/2 year tenure as President. Larry then worked for Smith & Nephew as a Director and Lobbyist until the end of 2005. Prior to joining Smith & Nephew, Larry was President of Memphis Light, Gas & Water Division from 1984 until his retirement in 1991. Larry was employed by MLG&W for 28 years. Larry has been a Member of the Board of Directors and Chairman of the Board of Directors of BioMimetic Therapeutics [NasdaqGM:BMTI] since August 2005. BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, periodontal, spine and sports injury applications. Larry has also served as a Member of the Board of Directors at Reaves Utility Income Fund [NasdaqCM:UTG], a closed-end management investment company, since February 2003, SSR Engineering, Inc. and AxioMed Spine Corporation. Larry graduated from Mississippi State University in 1963 with a Bachelor of Science in Civil Engineering. Larry has completed numerous professional development courses, including the American Management Association Management course, Senior Management course and President’s course. Larry has been very active in the Memphis Community and was General Campaign Chairman of United Way in 1987 and Chairman of the Board from 1990-92, President of Kiwanis Club and President of Junior Achievement. Currently, he is involved with several organizations, some of which are BioMimetic Therapeutics, Inc., BioMedical Tissue Technologies, Ltd. and the Shelby Farms Park Conservancy. Larry is married and has two grown children and five grandchildren. He is an avid golfer.
Follow Larry Papasan:
About MB Venture Partners: MEDOVEX’s management team and board of directors are highly experienced healthcare professionals in all functional areas
